{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:25:38Z","timestamp":1788474338485,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Recent investigations have demonstrated a relationship between the persistence of SARS-CoV-2 and post-COVID-19 conditions. Building upon a potential connection between SARS-CoV-2 persistence and early virologic rebound, we examine the association of early virologic rebound with post-acute mortality and hospitalization due to post-acute sequelae among hospitalized patients with COVID-19 in Hong Kong. Our study includes 13,859, 3959, and 4502 patients in the all-patient, nirmatrelvir\/ritonavir, and molnupiravir group, respectively. Results show that patients who experienced virologic rebound exhibited a significantly higher risk of post-acute mortality (hazard ratio [HR], 1.52; 95% confidence interval [CI], 1.36\u20131.70) with a risk difference [RD] of 7.19%, compared with patients without virologic rebound. A similar increase in the risk of post-acute mortality is also observed in nirmatrelvir\/ritonavir-treated patients (HR, 1.78; 95% CI, 1.41\u20132.25; RD, 12.55%) and molnupiravir-treated patients (HR, 1.47; 95% CI, 1.18\u20131.82; RD, 4.90%). The virologic rebound may thus serve as an early marker for post-COVID-19 condition, enabling healthcare officials to monitor and provide timely intervention for long COVID.<\/jats:p>","DOI":"10.1038\/s41467-025-61737-7","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T12:16:04Z","timestamp":1753704964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["SARS-CoV-2 rebound and post-acute mortality and hospitalization among patients admitted with COVID-19: cohort study"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5610-1298","authenticated-orcid":false,"given":"Ka Chun","family":"Chong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine Min","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1101-2045","authenticated-orcid":false,"given":"Christopher","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozhang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conglu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2103-8377","authenticated-orcid":false,"given":"Chi Tim","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoting","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie Ho Kwan","family":"Yam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsz Yu","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8722-6149","authenticated-orcid":false,"given":"Shi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3778-7068","authenticated-orcid":false,"given":"Kehang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0525-6772","authenticated-orcid":false,"given":"Chris Ka Pun","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4382-2445","authenticated-orcid":false,"given":"David SC","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1721-9450","authenticated-orcid":false,"given":"Eng Kiong","family":"Yeoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9002-0483","authenticated-orcid":false,"given":"Zihao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"61737_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101762","volume":"55","author":"LL O\u2019Mahoney","year":"2022","unstructured":"O\u2019Mahoney, L. L. et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. EClinicalMedicine 55, 101762 (2022).","journal-title":"EClinicalMedicine"},{"key":"61737_CR2","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.15585\/mmwr.mm7251a1","volume":"72","author":"DJ Smith","year":"2023","unstructured":"Smith, D. J., Lambrou, A. & Patel, P. SARS-CoV-2 rebound with and without use of COVID-19 oral antivirals. MMWR Morb. Mortal. Wkly Rep. 72, 1357\u20131364 (2023).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"61737_CR3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.7326\/M22-2381","volume":"176","author":"R Deo","year":"2023","unstructured":"Deo, R. et al. ACTIV-2\/A5401 study team. Symptom and viral rebound in untreated SARS-CoV-2 infection. Ann. Intern Med 176, 348\u2013354 (2023).","journal-title":"Ann. Intern Med"},{"key":"61737_CR4","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1056\/NEJMc2205944","volume":"387","author":"AS Anderson","year":"2022","unstructured":"Anderson, A. S., Caubel, P. & Rusnak, J. M. EPIC-HR trial investigators. Nirmatrelvir-ritonavir and viral load rebound in Covid-19. N. Engl. J. Med 387, 1047\u20131049 (2022).","journal-title":"N. Engl. J. Med"},{"key":"61737_CR5","doi-asserted-by":"publisher","first-page":"e2245086","DOI":"10.1001\/jamanetworkopen.2022.45086","volume":"5","author":"GL Wong","year":"2022","unstructured":"Wong, G. L. et al. Incidence of viral rebound after treatment with nirmatrelvir-ritonavir and molnupiravir. JAMA Netw. Open 5, e2245086 (2022).","journal-title":"JAMA Netw. Open"},{"key":"61737_CR6","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S1473-3099(22)00873-8","volume":"23","author":"CKH Wong","year":"2023","unstructured":"Wong, C. K. H. et al. Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: A population-wide retrospective cohort study. Lancet Infect. Dis. 23, 683\u2013695 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"61737_CR7","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.15585\/mmwr.mm7251a2","volume":"72","author":"PR Harrington","year":"2023","unstructured":"Harrington, P. R. et al. Evaluation of SARS-CoV-2 RNA rebound after nirmatrelvir\/ritonavir treatment in randomized, double-blind, placebo-controlled trials - United States and International Sites, 2021\u20132022. MMWR Morb. Mortal. Wkly Rep. 72, 1365\u20131370 (2023).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"61737_CR8","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.7326\/M23-1756","volume":"176","author":"GE Edelstein","year":"2023","unstructured":"Edelstein, G. E. et al. SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy: An observational study. Ann. Intern Med. 176, 1577\u20131585 (2023). Dec.","journal-title":"Ann. Intern Med."},{"key":"61737_CR9","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/cid\/ciad696","volume":"78","author":"SE Smith-Jeffcoat","year":"2024","unstructured":"Smith-Jeffcoat, S. E. et al. Symptoms, viral loads, and rebound among COVID-19 outpatients treated with nirmatrelvir\/ritonavir compared with propensity score-matched untreated individuals. Clin. Infect. Dis. 78, 1175\u20131184 (2024). May 15.","journal-title":"Clin. Infect. Dis."},{"key":"61737_CR10","doi-asserted-by":"crossref","unstructured":"Zuo W. et al. The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China. Lancet Infect. Dis. 2024:S1473-3099(24)00171-3.","DOI":"10.1016\/S1473-3099(24)00171-3"},{"key":"61737_CR11","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/s41586-024-07029-4","volume":"626","author":"M Ghafari","year":"2024","unstructured":"Ghafari, M. et al. Wellcome Sanger Institute COVID-19 Surveillance Team; COVID-19 Infection Survey Group; COVID-19 Genomics UK (COG-UK) Consortium; Barrett J, Fraser C, Bonsall D, Walker AS, Lythgoe K. Prevalence of persistent SARS-CoV-2 in a large community surveillance study. Nature 626, 1094\u20131101 (2024).","journal-title":"Nature"},{"key":"61737_CR12","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.13.06017","volume":"13","author":"KC Chong","year":"2023","unstructured":"Chong, K. C. et al. Changes in all-cause and cause-specific excess mortality before and after the Omicron outbreak of COVID-19 in Hong Kong. J. Glob. Health 13, 06017 (2023).","journal-title":"J. Glob. Health"},{"key":"61737_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","volume":"21","author":"HE Davis","year":"2023","unstructured":"Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol 21, 133\u2013146 (2023).","journal-title":"Nat. Rev. Microbiol"},{"key":"61737_CR14","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S2213-2600(23)00142-X","volume":"11","author":"C Yang","year":"2023","unstructured":"Yang, C., Zhao, H., Esp\u00edn, E. & Tebbutt, S. J. Association of SARS-CoV-2 infection and persistence with long COVID. Lancet Respir. Med 11, 504\u2013506 (2023).","journal-title":"Lancet Respir. Med"},{"key":"61737_CR15","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S2213-2600(22)00226-0","volume":"10","author":"S Hakki","year":"2022","unstructured":"Hakki, S. et al. ATACCC study investigators. Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: A prospective, longitudinal, community cohort study. Lancet Respir. Med. 10, 1061\u20131073 (2022).","journal-title":"Lancet Respir. Med."},{"key":"61737_CR16","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/s41423-020-00550-2","volume":"17","author":"F Hu","year":"2020","unstructured":"Hu, F. et al. A compromised specific humoral immune response against the SARS-CoV-2 receptor-binding domain is related to viral persistence and periodic shedding in the gastrointestinal tract. Cell Mol. Immunol. 17, 1119\u20131125 (2020).","journal-title":"Cell Mol. Immunol."},{"key":"61737_CR17","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/s41586-022-05542-y","volume":"612","author":"SR Stein","year":"2022","unstructured":"Stein, S. R. et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature 612, 758\u2013763 (2022).","journal-title":"Nature"},{"key":"61737_CR18","doi-asserted-by":"crossref","unstructured":"Perelson A. S., Ribeiro R. M., Phan T. An explanation for SARS-CoV-2 rebound after Paxlovid treatment. medRxiv [Preprint]. 2023 Jun 1:2023.05.30.23290747.","DOI":"10.1101\/2023.05.30.23290747"},{"key":"61737_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11936-022-00964-3","volume":"24","author":"SA Saha","year":"2022","unstructured":"Saha, S. A. et al. COVID-19 and cardiac arrhythmias: A contemporary review. Curr. Treat. Options Cardiovasc Med 24, 87\u2013107 (2022).","journal-title":"Curr. Treat. Options Cardiovasc Med"},{"key":"61737_CR20","doi-asserted-by":"publisher","first-page":"e2220184","DOI":"10.1001\/jamanetworkopen.2022.20184","volume":"5","author":"SB Ross","year":"2022","unstructured":"Ross, S. B. et al. Drug interactions with nirmatrelvir-ritonavir in older adults using multiple medications. JAMA Netw. Open 5, e2220184 (2022). Jul 1.","journal-title":"JAMA Netw. Open"},{"key":"61737_CR21","doi-asserted-by":"publisher","first-page":"e722","DOI":"10.1016\/S2666-5247(23)00146-5","volume":"4","author":"Y Lin","year":"2023","unstructured":"Lin, Y. et al. Viral kinetics of SARS-CoV-2 following onset of COVID-19 in symptomatic patients infected with the ancestral strain and omicron BA.2 in Hong Kong: a retrospective observational study. Lancet Microbe 4, e722\u2013e731 (2023). Sep.","journal-title":"Lancet Microbe"},{"key":"61737_CR22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jiph.2022.12.003","volume":"16","author":"L Pei","year":"2023","unstructured":"Pei, L. et al. Comorbidities prolonged viral shedding of patients infected with SARS-CoV-2 omicron variant in Shanghai: A multi-center, retrospective, observational study. J. Infect. Public Health 16, 182\u2013189 (2023). Feb.","journal-title":"J. Infect. Public Health"},{"key":"61737_CR23","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/infdis\/jiab107","volume":"224","author":"D Owusu","year":"2021","unstructured":"Owusu, D. et al. Household transmission study team. Persistent SARS-CoV-2 RNA shedding without evidence of infectiousness: A cohort study of individuals with COVID-19. J. Infect. Dis. 224, 1362\u20131371 (2021).","journal-title":"J. Infect. Dis."},{"key":"61737_CR24","doi-asserted-by":"publisher","first-page":"2002724","DOI":"10.1183\/13993003.02724-2020","volume":"58","author":"D Munker","year":"2021","unstructured":"Munker, D. et al. Dynamics of SARS-CoV-2 shedding in the respiratory tract depends on the severity of disease in COVID-19 patients. Eur. Respir. J. 58, 2002724 (2021).","journal-title":"Eur. Respir. J."},{"key":"61737_CR25","doi-asserted-by":"publisher","first-page":"e241765","DOI":"10.1001\/jamanetworkopen.2024.1765","volume":"7","author":"Z Yang","year":"2024","unstructured":"Yang, Z. et al. COVID-19 rebound after VV116 vs nirmatrelvir-ritonavir treatment: A randomized clinical trial: A randomized clinical trial. JAMA Netw. Open 7, e241765 (2024).","journal-title":"JAMA Netw. Open"},{"key":"61737_CR26","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.81849","volume":"11","author":"JA Hay","year":"2022","unstructured":"Hay, J. A. et al. Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: A retrospective cohort study. Elife 11, e81849 (2022).","journal-title":"Elife"},{"key":"61737_CR27","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/S1473-3099(22)00507-2","volume":"22","author":"CKH Wong","year":"2022","unstructured":"Wong, C. K. H. et al. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong\u2019s omicron BA.2 wave: a retrospective cohort study. Lancet Infect. Dis. 22, 1681\u20131693 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"61737_CR28","doi-asserted-by":"crossref","unstructured":"Wang H. et al. Association of nirmatrelvir-ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study. Lancet Infect Dis. 24, 1130\u20131140 (2024).","DOI":"10.1016\/S1473-3099(24)00217-2"},{"key":"61737_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102000","volume":"60","author":"ICH Lam","year":"2023","unstructured":"Lam, I. C. H. et al. Long-term post-acute sequelae of COVID-19 infection: a retrospective, multi-database cohort study in Hong Kong and the UK. EClinicalMedicine 60, 102000 (2023).","journal-title":"EClinicalMedicine"},{"key":"61737_CR30","doi-asserted-by":"crossref","unstructured":"Lin G. et al. Association of nirmatrelvir\/ritonavir with post-acute sequelae and mortality among immunocompromised patients with COVID-19: A real-world retrospective cohort study. Lancet Rheumatology7, e108\u2013e117 (2025).","DOI":"10.1016\/S2665-9913(24)00224-8"},{"key":"61737_CR31","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41591-020-0869-5","volume":"26","author":"X He","year":"2020","unstructured":"He, X. et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat. Med 26, 672\u2013675 (2020).","journal-title":"Nat. Med"},{"key":"61737_CR32","first-page":"147","volume":"21","author":"O Puhach","year":"2023","unstructured":"Puhach, O., Meyer, B. & Eckerle, I. SARS-CoV-2 viral load and shedding kinetics. Nat. Rev. Microbiol 21, 147\u2013161 (2023).","journal-title":"Nat. Rev. Microbiol"},{"key":"61737_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02220-0","volume":"20","author":"JD Challenger","year":"2022","unstructured":"Challenger, J. D. et al. Modelling upper respiratory viral load dynamics of SARS-CoV-2. BMC Med 20, 25 (2022).","journal-title":"BMC Med"},{"key":"61737_CR34","unstructured":"Cycle threshold (Ct) in SARS-CoV-2 RT-PCR. Gov.uk. 2020 [cited 2024 Jul 20]. Available from: https:\/\/www.gov.uk\/government\/publications\/cycle-threshold-ct-in-sars-cov-2-rt-pcr"},{"key":"61737_CR35","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2421397","volume":"13","author":"H Wang","year":"2024","unstructured":"Wang, H. et al. COVID-19 vaccination modified the effect of nirmatrelvir-ritonavir on post-acute mortality and rehospitalization: a retrospective cohort study. Emerg. Microbes Infect. 13, 2421397 (2024).","journal-title":"Emerg. Microbes Infect."},{"key":"61737_CR36","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2025.2469648","volume":"14","author":"Y Wei","year":"2025","unstructured":"Wei, Y. et al. Effectiveness of nirmatrelvir\/ritonavir and molnupiravir on post-COVID-19 outcomes among outpatients: a target trial emulation investigation. Emerg. Microbes Infect. 14, 2469648 (2025).","journal-title":"Emerg. Microbes Infect."},{"key":"61737_CR37","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/CIRCOUTCOMES.113.000359","volume":"6","author":"MA Brookhart","year":"2013","unstructured":"Brookhart, M. A., Wyss, R., Layton, J. B. & St\u00fcrmer, T. Propensity score methods for confounding control in nonexperimental research. Circ. Cardiovasc Qual. Outcomes 6, 604\u2013611 (2013).","journal-title":"Circ. Cardiovasc Qual. Outcomes"},{"key":"61737_CR38","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PC Austin","year":"2009","unstructured":"Austin, P. C. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun. Stat. Simul. Comput 38, 1228\u20131234 (2009).","journal-title":"Commun. Stat. Simul. Comput"},{"key":"61737_CR39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.annepidem.2006.10.009","volume":"17","author":"R Li","year":"2007","unstructured":"Li, R. & Chambless, L. Test for additive interaction in proportional hazards models. Ann. Epidemiol. 17, 227\u2013236 (2007).","journal-title":"Ann. Epidemiol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61737-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61737-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61737-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T04:23:11Z","timestamp":1757305391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61737-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["61737"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-61737-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6924"}}